Introduction
The nuclear proto-oncogene c-jun encodes for a major component of the activator protein-1 (AP-1) transcription factor family comprising the jun, fos and CREB/ ATF proteins. c-jun homodimerizes or heterodimerizes with AP-1 family members via the leucine-zipper domain (Halazonetis et al., 1988) , and recognizes TPA-or cAMP-response elements in promoters. The c-jun promoter contains two variant AP-1 binding sites, where the c-jun protein preferentially heterodimerizes with ATF-2 (Stein et al., 1992; van Dam et al., 1993) . The more proximal AP-1 (pAP-1) site is the main site at which c-jun stimulates its own transcription in a positive autoregulatory loop (Angel et al., 1988) . For transcriptional and autoregulatory activity, c-jun requires phosphorylation by the Jun N-terminal kinase (JNK) at serine 63 (Ser63) and serine 73 (Ser73) within the transactivation domain (Pulverer et al., 1991) . The JNK signaling pathway connects c-jun to a variety of extracellular factors, including growth factors and cytokines. In response, c-jun regulates crucial biological processes, such as proliferation, apoptosis or differentiation.
A deregulation of c-jun or JNK can, however, also promote cellular transformation. Besides important oncogenes like Ha-ras (Schutte et al., 1989) , cot (Chiariello et al., 2000) or met (Rodrigues et al., 1997) , leukemic translocations have also been shown to stimulate tumor promotion and oncogenic transformation by overexpression of c-jun. In the chronic myeloid leukemia (CML)-associated leukemic translocations t(9;22) or t(3;21), enhanced AP-1 activity has been implicated in the leukemic transformation process Raitano et al., 1995; Tanaka et al., 1995) . Studies on t(9;22) have revealed that the resulting BCR-ABL fusion gene constitutively activates the JNK signaling pathway and increases c-jun expression (Burgess et al., 1998) . Enhanced c-jun expression and JNK activity might also play a role in acute myeloid leukemia (AML) with frequently observed balanced rearrangements such as t(8;21). Overexpression of the AML1-ETO fusion gene, resulting from the translocation t(8;21) in fibroblast cells, results in transformation and has been associated with increased levels of phosphorylated c-jun and enhanced AP-1 activity (Frank et al., 1999) . The pathophysiological importance of these findings, however, has not been confirmed in primary leukemia patient samples on the basis of increased levels of c-jun expression. Furthermore, the importance of the JNK signaling pathway for AML1-ETO induced leukemogenesis has not been investigated.
The translocation t(8;21) is associated with about 40% of AML with FAB (French-American-British) subtype M2 and represents one of the most frequent chromosomal translocations in AML (Look, 1997) . The resulting AML1-ETO fusion gene inhibits important myeloid transcription factors, which might lead to the block in differentiation (Vangala et al., 2003) . It has recently been shown that AML1-ETO might also be responsible for gain-of-function properties characterizing leukemogenesis (Mulloy et al., 2002) . Expression of AML1-ETO in primary human CD34 þ stem cells results in a proliferation and survival advantage of leukemic cells, and thus promotes their expansion (Mulloy et al., 2002) . Several positively regulated target genes of AML1-ETO have been identified, but only a few have been confirmed in primary t(8;21)-positive cells. Furthermore, the molecular mechanisms behind the gain-of-function properties of AML1-ETO are still unknown.
In this study, we found that AML patient cells with the translocations t(8;21), t(15;17) or inv(16) have increased expression levels of c-jun. Moreover, in t(8;21)-positive patient cells, there was a correlation in the mRNA expression levels of AML1-ETO and c-jun. We show that AML1-ETO induces upregulation of cjun expression via transactivation of the c-jun promoter, and mapped the AML1-ETO responsive site to the proximal AP-1 site. We also demonstrate the importance of the JNK signaling pathway for AML1-ETO induced c-jun activation and for the biological function of AML1-ETO. Finally, we suggest that an autocrine loop involving granulocyte-colony stimulating factor (G-CSF) and the G-CSF receptor (G-CSF-R) participates in AML1-ETO induced JNK signaling.
Results
High c-jun mRNA expression in AML patient cells with t(8;21), t(15;17) or inv(16), and correlation in mRNA expression levels of AML1-ETO and c-jun within t(8;21)-positive AML cells CML leukemia cells with translocation t(9;22) have previously been associated with increased c-jun expression levels (Burgess et al., 1998) . We therefore examined whether mRNA expression levels for c-jun are also elevated in AML leukemia cells with the most common cytogenetic abnormalities. Microarray analysis (Affymetrix) was performed on AML patient samples with translocation t(8;21), t(15;17), inv(16), with translocations involving the mixed-lineage-leukemia (MLL) gene A-E -ret.lys.
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A-E -ret.lys. To investigate whether AML1-ETO induction also increases c-jun protein levels, Western blot experiments were performed using a tetracycline-regulated AML1-ETO expressing U937 cell line (U937T/A-E), which expresses high and tightly controlled levels of AML1-ETO protein upon tetracycline withdrawal ( Figure 2b , upper panel) (Burel et al., 2001 ). In the U937T/A-E cell line, c-jun protein (39 kDa) expression was increased after 24 h of AML1-ETO induction, and increased up to 21-fold after 72 h of induction ( Figure 2b , middle panel). In the U937T control cell line, c-jun protein expression did not change upon tetracycline-withdrawal ( Figure 2b , lower panel). These data indicate that in U937 cells, AML1-ETO induction increases c-jun mRNA and c-jun protein expression levels.
AML1-ETO enhances the positive autoregulatory activity of c-jun by transactivating the human c-jun promoter through the proximal AP-1 site
We next studied whether AML1-ETO upregulated c-jun expression by stimulating c-jun promoter activity. Furthermore, it was of interest to compare the transactivating capacity of AML1-ETO with wild-type AML1 or ETO protein. We transiently transfected U937 cells with the full-length human c-jun promoter (construct #1) and cotransfected AML1-ETO, AML1 or ETO. AML1-ETO transactivated the full-length c-jun promoter around threefold, whereas neither wild-type AML1, with or without cotransfection of its coactivator core-binding factor (CBF) b, nor wild-type ETO had transactivation capacity (Figure 3b ).
In order to map the AML1-ETO transactivation site in the c-jun promoter, we transiently transfected U937 cells with various 5 0 c-jun promoter deletion mutants (Wei et al., 1998) . In Figure 3a , the basal promoter activity of each promoter construct in U937 cells is presented in comparison to the basal promoter activity of the empty vector plasmid pGL3 or pGL2. The site transactivated by AML1-ETO could be narrowed down to a region between bp À180/ þ 731 (construct #5) (about 3.5-fold transactivation) and bp À63/ þ 731 (construct #6) (no transactivation) (Figure 3c ). In the longer c-jun promoter constructs (#2-4), transactivation capacity of AML1-ETO decreased from threefold to 1.5-fold, which implies loss of positive-response elements. In addition, the increase in c-jun activation by AML1-ETO upon removal of sequence between À345 and À180 suggests the presence of a repressive element (possibly the distal AP-1 site). The bp À180/ þ 731 c-jun promoter construct (#5) still contains the proximal AP-1 site ( Figure 3a ). The importance of the AP-1 site for AML1-ETO transactivation has previously been shown using a minimal AP-1 promoter derived from the collagenase gene in fibroblast cells (Frank et al., 1999) .
For fine mapping, U937 cells were transiently transfected with a c-jun promoter construct (bp À79/ þ 170) (#7) containing the proximal AP-1 site (pAP-1), or the same construct with a mutated pAP-1 site (#8) (Figure 3d ). Cotransfection of AML1-ETO transactivated the bp À79/ þ 170 c-jun promoter construct up to 4.5-fold, whereas transactivation capacity was reduced to 1.5-fold when the pAP-1 site was mutated. The bp À63/ þ 170 c-jun promoter construct (#9) was not transactivated by AML1-ETO (Figure 3d ). This construct was included to rule out a role of the 3 0 promoter region between bp þ 170 and bp þ 731. The pAP-1 site is also the site through which c-jun autoregulates its own expression. We therefore hypothesized that AML1-ETO enhanced the autoregulatory capacity of c-jun by increasing c-jun protein levels. We transiently transfected the full-length c-jun promoter (#1), and cotransfected c-jun, AML1-ETO, or c-jun and AML1-ETO together, into U937 cells, which contain little endogenous c-jun. Cotransfection of AML1-ETO increased transactivation capacity of c-jun from fourfold to 10-fold ( Figure 3e ). These results show that AML1-ETO increased c-jun promoter activity via the proximal AP-1 site and thus enhanced the autoregulatory nature of c-jun.
AML1-ETO induces the JNK signaling pathway
We investigated how AML1-ETO induced c-jun promoter activity. AML1-ETO could not directly bind to the c-jun promoter (EMSA, data not shown) and in addition, the c-jun promoter does not contain any AML1 consensus sites through which AML1-ETO has been shown to interact with DNA (Meyers et al., 1993) . Therefore, AML1-ETO might induce the c-jun promoter via the proximal AP-1 site in an indirect manner. At the proximal AP-1 site, prebound c-jun is mainly targeted by the JNK signaling pathway (Karin, 1995) . We therefore hypothesized that the JNK signaling pathway might be involved. We assayed the activity of JNK induced phosphorylation of Ser63 in c-jun in U937T/A-E cells after 48 h of AML1-ETO induction (U937T/A-E 48 h Àtet) and found a 3.5-fold increase. (Figure 4a , lane 4). Tetracycline withdrawal did not affect c-jun phosphorylation in U937T control lysates (U937T 48 h Àtet) (Figure 4a , lanes 1 and 2).
In order to rule out the possibility that kinases other than JNK phosphorylated Ser63 in c-jun, we directly measured phosphorylation of JNK upon AML1-ETO induction. AML1-ETO induction for 48 h increased phosphorylation of the 46 kDa isoform of JNK up to 2.3-fold and the 54 kDa isoform of JNK up to 6.3-fold (Figure 4b ). Unphosphorylated JNK1 expression levels were, however, not enhanced upon AML1-ETO induction (Figure 4c ). We further analysed the phosphorylation of the endogenous JNK targets c-jun and ATF-2 upon AML1-ETO expression, which heterodimerize at the proximal AP-1 site in U937 cells (data not shown). AML1-ETO induction also increased JNK-specific phosphorylation of Ser73 in c-jun up to 2.5-fold and c-jun and JNK in t (8;21) AML A Elsässer et al phosphorylation of Thr71 in ATF-2 up to 3.2-fold. (Figure 4d ). These results indicate that the JNK signaling pathway might link the expression of AML1-ETO with transactivation of the proximal AP-1 site of the c-jun promoter.
Interference with the JNK signaling pathway disrupts the functional properties of AML1-ETO In order to elucidate the functional importance of the JNK signaling pathway for AML1-ETO induced transactivation of c-jun promoter activity, we investigated whether disruption of the JNK signaling pathway could interfere with the transactivation capacity of AML1-ETO on the c-jun promoter. For this, U937T/ A-E and U937T control cells, grown with or without tetracycline, were transiently transfected with the fulllength c-jun promoter construct (#1), and cotransfected with JIP-1 (Figure 5a ). JIP-1, a scaffold protein, aggregates components of the JNK pathway to form a functional signaling module (Yasuda et al., 1999) . In overexpression studies, however, JIP-1 sequesters JNK from its nuclear targets, and thus functions as an inhibitor of JNK-regulated gene expression (Dickens et al., 1997) . We could show that JIP-1 inhibited the activating effects of c-jun on the c-jun promoter. Figure 5d ). Therefore, we overexpressed JIP-1 in U937T/A-E cells after 36 h of AML1-ETO induction and found that the transactivation capacity of the c-jun promoter by AML1-ETO was reduced from threefold to 1.7-fold (40%) (Figure 5a ). We further assessed whether the inhibition of c-jun activation could inhibit the biological functions of AML1-ETO. AML1-ETO induction for 3 days in U937 cells induces proliferation arrest and apoptosis (Burel et al., 2001) . We confirmed the proapoptotic function of AML1-ETO in these cells by performing Western blot analysis for poly(ADP-ribose) polymerase (PARP). PARP is a 116 kDa protein that is specifically cleaved by caspase-3 and caspase-6 into a 85 kDa apoptotic fragment. We found that after 72 h of AML1-ETO induction, the 116 kDa PARP protein was cleaved to a 85 kDa apoptotic fragment (Figure 5c ). Annexin V/propidium iodide staining revealed that these apoptotic cells are mainly in the stage of late apoptosis (Figure 5b) .
We tried to block AML1-ETO induced apoptosis with cell-permeable JNK inhibitor peptides (JNK inh.). They contain 20 amino acids of the islet-brain-1 protein, a mouse homologue of JIP-1 (Bonny et al., 2001) , and reduced the amount of AML1-ETO induced phosphorylation of Ser63 in c-jun by 60% (from 1 to 0.4, according to Densitometric analysis) (Figure 5e ). Furthermore, they inhibited the autoregulatory activity of c-jun on the c-jun promoter. (Figure 5d ). Addition of these peptides to AML1-ETO expressing U937T/A-E cells reduced AML1-ETO induced apoptosis by 30%, while addition of a negative control peptide (HIV-TAT alone) had no effect. No effect was seen when U937T/A-E cells were grown in the presence of tetracycline or for the U937T control cell line (Figure 5b ). These results demonstrate the importance of the JNK signaling pathway and c-jun activation for the functional properties of AML1-ETO.
An autocrine growth factor loop involving G-CSF and its receptor is important for JNK phosphorylation in AML1-ETO expressing cells
The question remains, how AML1-ETO, which has no known kinase activity, induced the JNK signaling pathway. AML1-ETO has recently been shown to upregulate the expression of the G-CSF-R (Shimizu et al., 2000) , which can mediate Ras-dependent activation of the JNK signaling pathway (Rausch and Marshall, 1997) . Therefore, we analysed the microarray analysis data on leukemic patient samples, as described in Figure 1a , for mRNA expression levels of the G-CSF-R. We found that t(8;21)-, t(15;17)-or inv(16)-positive AML cells and also CML cells contained significantly higher expression levels of G-CSF-R mRNA than normal bone marrow cells (Figure 6a ). We then examined the mRNA and protein expression levels of the G-CSF-R and its ligand G-CSF in U937T/A-E and U937T control cells upon tetracycline withdrawal by real-time PCR and Western blot analysis, respectively. AML1-ETO induction in the U937T/A-E cells increased -4) , or GST beads alone (lanes 5 and 6). After kinase reaction, cell lysates were blotted for JNK-dependent phosphorylation of Ser63 in c-jun. As loading control, the same blot was reblotted with a GST antibody. Densitometric analysis of the GST c-jun P (Ser63)/ GST c-jun ratios are presented in bold as fold change compared to the cell lines without induction ( þ tet), which are set to onefold. the G-CSF-R mRNA expression up to 3.8-fold and protein expression up to 3.6-fold (Figure 6b) . The expression of G-CSF increased after AML1-ETO expression up to sixfold on mRNA and up to threefold on protein level (Figure 6c) .
To test whether G-CSF and its receptor are important for activating JNK signaling pathways in AML1-ETO expressing cells, we stimulated U937T/A-E cells after 48 h of AML1-ETO induction with a G-CSF-R-neutralizing antibody. This antibody interacts with the ligand-binding domain of the G-CSF-R and inhibits binding of G-CSF. We found that the elevated levels of phosphorylated p46 and p54 isoforms of JNK in AML1-ETO expressing cells were reduced by about 10-fold after addition of G-CSF-R-neutralizing antibody. Exogenous G-CSF further stimulated JNK phosphorylation in these cells two-to threefold, which was reduced after addition of G-CSF-R-neutralizing antibodies (Figure 6d ). These results indicate that G-CSF and G-CSF-R expression levels are upregulated in AML1-ETO expressing cells. Furthermore, G-CSF and the G-CSF-R pathways are functional and participate in AML1-ETO induced JNK signaling.
Discussion
Approximately 40% of AML is associated with the translocations t(8;21), t(15;17), inv(16) or t(9;11), encoding for the AML1-ETO, PML-RARa, CBFb-SMMHC and MLL-AF9 fusion proteins, respectively (Look, 1997) . Despite the diversity of the involved fusion partners, these AML-associated chimeric proteins deregulate their target genes through common mechanisms (Alcalay et al., 2001) . We suggest that these AML fusion proteins might also affect common targets and show in the present study that proto-oncogene c-jun was a frequently upregulated target gene (Figure 1a ). In the case of t(8;21), we identified that AML1-ETO, by employing an indirect mechanism including the JNK signaling pathway, upregulated c-jun expression through the proximal AP-1 site.
Previous studies have indicated that specific signaling events might be important for the functional properties ). U937T/A-E cells were grown for 48 h in the absence of tetracycline (U937T/A-E 48 h-tet) and stimulated for 10 min with either 5 mg/ml of G-CSF-R-neutralizing antibody (G-CSFR NAB), 10 ng/ml human recombinant G-CSF or with G-CSFR NAB and G-CSF together. Densitometric analyses of the p54 and p46/btubulin ratios are presented in bold of AML1-ETO. Transformation capacities of AML1-ETO in NIH3T3 cells have been associated with elevated levels of phosphorylated c-jun (Frank et al., 1999) . In addition, wild-type ETO requires H-Ras for transformation of 3T3 fibroblast cells (Sueoka et al., 1998) . Therefore, pathways like the JNK pathway, which are both Ras-and c-jun dependent are candidate mechanisms for AML1-ETO-dependent signaling. Unlike leukemic fusion proteins such as BCR-ABL, AML1-ETO has no known intrinsic kinase activity on its own. Thus, it appears more likely that it interferes with such signaling pathways in an indirect manner. We propose that an autocrine mechanism involving G-CSF and the G-CSF-R participates in AML1-ETO-mediated JNK signaling ( Figure 6 ). It has previously been shown that primary AML blast cells can produce and respond to their own growth factors, like G-CSF, GM-CSF or IL-1b, which allow them to grow autonomously (Bradbury et al., 1992) . Moreover, administration of G-CSF stimulates cell growth (Spinner et al., 1995; Baumann et al., 2001) by activating the JNK signaling pathway (Rausch and Marshall, 1999) and c-jun expression (Brandstetter et al., 1998) . In IL-3-dependent cell lines, AML1-ETO expression has been shown to lead to G-CSF-dependent proliferation (Kohzaki et al., 1999) . Furthermore, AML1-ETO promotes the expansion and self-renewal capacities of human CD 34 þ stem cells, which is the cell type, in which the translocation is physiologically found (Mulloy et al., 2002) . The mechanism is currently unknown, but an involvement of AML1-ETO in G1-to S-phase progression is discussed, as wild-type AML1 has been shown to inhibit cell cycle progression (Lou et al., 2000) . c-jun also has been implicated in G1-to S-phase progression and cell proliferation by negatively regulating tumor suppressors and cell cycle regulators (Schreiber et al., 1999; Rangatia et al., 2002; Peer Zada et al., 2003) . The functional properties of AML1-ETO are strongly depending on the maturation stage of the progenitor cells. Thus, AML1-ETO expression in more mature progenitor cells results in growth arrest and abrogates colony formation (Mulloy et al., 2002) . AML1-ETO induction in CD34-myeloid U937 cells reduces proliferation and the cells undergo apoptosis after 3 days (Burel et al., 2001) , (Figure 5b, c) . Our data indicate that the JNK signaling pathway and c-jun activation are important for the proapoptotic function of AML1-ETO in U937 cells (Figure 5b) . Therefore, we suggest that AML1-ETO and c-jun might share additional functional properties.
In primary t(8;21)-positive cells, we could further show a correlation of AML1-ETO and c-jun expression levels (Figure 1d ). The biological relevance of the lower levels of c-jun and AML1-ETO expression in some of the t(8;21)-positive samples is unknown. A follow-up study on the expression levels of AML1-ETO and c-jun might give important insights whether patients with lower levels of AML1-ETO and c-jun reach complete remission more rapidly or show a prolonged event free survival (EFS).
Upregulated c-jun expression in CML has been shown to be important for proliferation and transformation properties of leukemia blast cells Raitano et al., 1995; Tanaka et al., 1995) . Thus, disruption of the c-jun regulating JNK pathway might have therapeutic potential in AML, as similarly shown in rheumatoid arthritis (Han et al., 1999) or diabetes (Bonny et al., 2001) . Alternatively, the higher proliferative activity of AML blast cells from patients of the favorable subgroup, including t(8;21), t(15;17) and inv(16), might be beneficial during standard chemotherapy, as it increases sensitivity to S-phase-specific agents such as cytosine arabinoside (AraC) (Braess et al., 2001) . Intriguingly, we found high levels of c-jun expression in AML cells with translocations t(8;21), t(15;17) or inv(16), which are associated with good response to AraC, whereas c-jun expression was low in cells with translocation t(11q23/MLL), which are generally associated with worse prognosis (Bloomfield et al., 2002) ( Figure 1a ). The good prognosis subgroups are also more likely to produce endogenous G-CSF, GM-CSF or IL-3 (Braess et al., 2001) . Furthermore, t(8; 21)-(Shimizu et al., 2000) and t(15;17)-positive patient cells have previously been shown to contain high levels of G-CSF-R, and t(15;17)-positive cells proliferate in response to G-CSF which increases their vulnerability to cell-cyclespecific drugs (Katayama et al., 1998) . Accordingly, we show here that AML patient cells of the 'favorable' subgroups contained increased mRNA expression levels of the G-CSF-R (Figure 6a ). The similar expression pattern of the G-CSF-R and c-jun mRNA expression in AML cells with the most common translocations (Figures 1a and 6a) further indicates that the G-CSF-R and c-jun might participate in the same signal transduction pathway. This is the first report presenting data that the leukemic fusion protein AML1-ETO induces autocrine loops involving G-CSF and the G-CSF-R, resulting via JNK stimulation in increased expression levels of protooncogene c-jun (Figure 7) . We identified c-jun as a common target among 'good prognosis' AML, and propose that this knowledge might be valuable for the therapeutic outcome of other AMLs.
Materials and methods

Cells and cell culture
A human myeloblastic U937 cell line containing the AML1-ETO cDNA under the control of the human metallothionein promoter in the expression vector pPC18 (U937Z/A-E) was kindly provided by PG Pelicci (Instituto Europeo di Oncologia, Milano). U937Z/A-E, parental U937 cells (DSMZ: ACC5) and AML1-ETO expressing Kasumi-1 cells (DSMZ: ACC220) were grown in RPMI 1640 medium (PAN Biotech, Aidenbach, Germany) supplemented with 10% FBS and 1% l-Glutamine (Gibco BRL, Rockville, MD, USA). An inducible AML1-ETO expressing U937T cell line under control of the tetracycline (tet)-responsive transcriptional repressor tTA (U937T/A-E) and an empty vector cell line containing tTA (U937T) were as described (Burel et al., 2001) . Recombinant c-jun and JNK in t (8;21) AMLhuman G-CSF was added at a concentration of 10 ng/ml (Granocyte 34, Chugai, Frankfurt, Germany). Bioactive, cellpermeable JNK inhibitor I peptides (420116) and negative control peptides (420118) were purchased from Calbiochem (Schwalbach, Germany) and used as described (Bonny et al., 2001) .
Patient samples
Patient samples were referred to the Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Hospital Grosshadern, for routine cytomorphologic and cytogenetic analyses. All samples were from the time of diagnosis and selected for mononuclear cells by Ficoll gradient separation. The percentage of blast cells within the bone marrow carrying the respective fusion genes as detected by fluorescence in situ hybridization ranged from 52 to 99% (median 90%). There was no correlation between the percentage of blast cells and the fusion gene transcript levels. Leukemia patient samples analysed by microarray analysis had only a single translocation, the group of t(11q23/MLL)-positive patients samples contained one sample with a t(11;19), one sample with a t(6;11), one with a t(11;22), and seven samples with a t(9;11) (Figures 1a and 6a) . Microarray analysis was performed as described (Schoch et al., 2002) . In the t(8;21)-positive patients analysed by real-time PCR (Figure 1b, c) , four patients had t(8;21) as sole anomaly, 13 had loss of a sex chromosome, two had trisomy 8, and one a t(15;20). The AML1-ETO transcript was observed in all cases.
Quantitative real-time RT-PCR
For total RNA isolation, the Rneasy Mini kit (Qiagen, Hilden, Germany) was used according to the manufacturer's instructions. Total RNA (1 mg) was reversely transcribed using the Omniscript Reverse Transcriptase protocol (Qiagen, Hilden, Germany). Real-time PCR was performed using the LightCycler FastStart DNA Master SYBR Green I kit (Roche Diagnostics, Mannheim, Germany) as described (Reddy et al., 2002) . Primers for G6PD (Emig et al., 1999) , c-jun (Kiaris et al., 1999) and G-CSF-R (Brandstetter et al., 1998) were as described. AML1-ETO primers were designed with the sense primer lying in the region of AML1: 5 0 -ATG ACC TCA GGT TTG TCG GTC G-3 0 and the antisense primer in the breakpoint region of AML1-ETO: 5 0 -TGA ACT GGT TCT TGG AGC CTC CT-3 0 . G-CSF primers were as follows: sense: 5 0 -GCT TGA GCC AAC TCC ATA GC-3 0 ; antisense: 5 0 -AAA TGC AGG GAA GGA CAC AG-3 0 . Linearized G6PD plasmid: pGdBBX, kindly provided by Andreas Hochhaus, was serially diluted and used as a standard curve. Sizes of the amplified product performed in the LightCycler were verified by electrophoresis through 1% ethidium bromide stained agarose gels: c-jun: 409 bp, G6PD: 343 bp, G-CSF-R: 276 bp, G-CSF: 591 bp and AML1-ETO: 250 bp.
Western blot, antibodies
Cells were lysed in Ripa buffer, and proteins analysed by Western blot as described Reddy et al., 2002) . Densitometric analysis was performed using the AIDA 2.1 software program. In vitro translated c-jun and AML1-ETO were prepared as described (Behre et al., 1999b) using the TnT SP6-coupled reticulocyte lysate system (Promega, Madison, WI, USA). Phosphorylated antibodies and the nonradioactive SAPK/JNK Assay kit were used according to the manufacturer's instructions (New England Biolabs, Schwalbach, Germany). G-CSF-R-neutralizing antibodies were applied at a concentration of 5 mg/ml (Chemicon, Temecula, CA, USA). All other antibodies were obtained from Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Reporter constructs and expression plasmids
The human full-length c-jun promoter and various 5 0 truncation mutants in the firefly luciferase vector pGL3 were a kind gift of Wayne Vedeckis (State University Medical Center, New Orleans, USa) (Wei et al., 1998) . The bp À79/ þ 170 proximal c-jun promoter construct and the AP-1/CRE mutation of the same in pGL2 were kindly provided by Xiao-Fan Wang (Duke University Medical Center, Durham, NC, USA) (Wong et al., 1999) . For generation of the bp À63/ þ 170 c-jun promoter construct in pGL2, the fragment was PCR amplified using sense 5 0 -TGG GCT ATT TTT AGG GGT TGA CTG G-3 0 and antisense: 5 0 -AGC CAC AGG CGC TAG CTC TGG G-3 0 , cloned into pCR2.1 using TOPO TA cloning strategy (Invitrogen, Groningen, The Netherlands) and subcloned into pGL2 via Kpn/XhoI sites. Expression plasmids for AML1-ETO, ETO, AML1 or CBFb in pCMV5 were kindly provided by Scott Hiebert (St Jude Children's Hospital, Memphis, Tennessee, USA). Mouse c-jun was a kind gift of Trang Hoang (Clinical Research Institute of Montreal, QC, Canada). Fulllength flag-tagged JIP-1 in pCMV5 was provided by Roger Davis (Howard Hughes Medical Institute, MA, USA). Mouse c-jun in pSP65 for in vitro translation has been described (Behre et al., 1999b) . AML1-ETO for in vitro translation was generated by subcloning AML1-ETO from pCMV5 into pCDNA 3.1( þ ) (Invitrogen, Groningen, The Netherlands) via XbaI site.
Transient transfections and luciferase reporter assays U937 cells were transiently transfected using Effectene transfection reagent according to the manufacturer's protocol (Qiagen, Hilden, Germany). Cells were split 24 h prior to transfection to 3 Â 10 5 cells/ml and harvested 30 h posttransfection.
U937T and U937T/A-E cells were kept in the maintenance medium with and without tetracycline for 12 h prior to transfection and harvested 24 h after transfection. The dualluciferase reporter assay system (Promega, Madison, WI, USA) was performed as previously described (Behre et al., 1999a, c) . 
Detection of apoptosis
Apoptosis was detected by Western blot analysis for PARP. The level of apoptosis was further assessed by flow cytometry of cells stained with AnnexinV-FITC and propidium iodide as described by the manufacturer (NX50; R&D systems, Wiesbaden, Germany).
Statistical analysis
A correlation coefficient (r), and the respective P-value for statistical significance were calculated. The Mann-WhitneyWilcoxon test was performed to compare the median of two groups. Based on the number of patient samples analysed, a Pvalue p0.05 indicated statistically significant difference between two groups.
